Edition:
United Kingdom

People: argenx SE (ARGX.BR)

ARGX.BR on Brussels Stock Exchange

131.70EUR
10:13am BST
Change (% chg)

€0.30 (+0.23%)
Prev Close
€131.40
Open
€131.60
Day's High
€132.20
Day's Low
€130.30
Volume
19,614
Avg. Vol
107,150
52-wk High
€132.40
52-wk Low
€54.30

Leighton, Trevor 

Mr. Trevor Leighton serves as Vice President Market Access at argenx SE. He has over 20 years proven experience in market access and strategic planning Trevor joined argenx after completing a short period consulting. Prior to this Mr. Trevor worked for Shire, which he joined in 2007 to establish an International Speciality Market Access capability, where none existed previously, going on to become Head of International Market Access and then Head of Global Value Strategy & Access for Shire specialty and rare disease portfolios. With Shire, Trevor and the team he built supported multiple successful launches of new therapies across six continents. Trevor joined Shire after 17 years with Novartis first in the UK and then in Basel, Switzerland where he became Head of Market Access & Health Economics for the Respiratory & Dermatology Business Franchises including the launch of omalizumab for severe allergic asthma outside of the USA. Trevor has a Master’s in Business Administration from the University of Brunel / Henley Management College, a Diploma in Marketing from the UK Chartered Institute of Marketing and a Bachelors degree in Zoology with Botany from the University of London.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --